Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  • Attrezzature
  1. Pubblicazioni

The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives

Articolo
Data di Pubblicazione:
2025
Citazione:
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives / Cigliola, A., Maiorano, B.A., Dengur, D., Tateo, V., Mercinelli, C., Piacentini, M., Inguglia, S., Messina, C., Necchi, A.. - In: CANCERS. - ISSN 2072-6694. - 17:24(2025). [10.3390/cancers17244017]
Abstract:
Background: Muscle-invasive bladder cancer (MIBC) represents a highly aggressive malignancy associated with significant morbidity and mortality. The current standard treatment, which includes radical cystectomy and platinum-based chemotherapy, is burdened by high toxicity and a substantial risk of relapse. For this reason, over the past decade, novel therapeutic strategies involving immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), and targeted therapies have been investigated. This review aims to summarize current clinical evidence and ongoing trials evaluating these approaches in the perioperative setting. Methods: A systematic search was conducted using PubMed, EMBASE, and Cochrane databases, along with abstracts from major oncology conferences (ASCO, ESMO, SGO). Clinical trials assessing ICIs, ADCs, and targeted therapies, either alone or in combination with each other or with chemotherapy, in MIBC, were included. Results: Several early-phase and phase III trials have investigated the perioperative management of MIBC. Various studies evaluated the addition of ICIs to standard chemotherapy, demonstrating promising results in terms of pathological complete response. In parallel, the encouraging outcomes with ICIs and ADCs alone in the neoadjuvant or adjuvant setting paved the way for their combination in integrated strategies. Biomarker-driven approaches, based on circulating tumor DNA and specific genomic alterations, are being actively explored to improve patient selection and personalize treatment. Conclusions: ICIs, ADCs, and targeted therapies are reshaping the therapeutic landscape of MIBC. While early results are promising, further data and biomarker validation are essential to establish their definitive role and guide clinical decision-making in the perioperative setting.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
MIBC; antibody–drug conjugates; bladder preservation; immune checkpoint inhibitors; muscle-invasive bladder cancer; neoadjuvant; perioperative therapy; radical cystectomy
Elenco autori:
Cigliola, Antonio; Maiorano, Brigida Anna; Dengur, Doga; Tateo, Valentina; Mercinelli, Chiara; Piacentini, Michela; Inguglia, Sara; Messina, Carlo; Necchi, Andrea
Autori di Ateneo:
NECCHI ANDREA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/207999
Pubblicato in:
CANCERS
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.11.1.0